Status:
TERMINATED
Rosiglitazone Versus Placebo in Chronic Stable Angina
Lead Sponsor:
University of Glasgow
Collaborating Sponsors:
British Heart Foundation
GlaxoSmithKline
Conditions:
Angina Pectoris
Metabolic Syndrome X
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
We wish to see if the drug rosiglitazone, currently used in the treatment of type 2 diabetes, could be used as a new treatment for angina when compared with placebo in overweight subjects who do not h...
Detailed Description
Chronic stable angina is a common manifestation of ischaemic heart disease. Current mechanical therapies (percutaneous coronary intervention and coronary artery bypass grafting) and pharmacological th...
Eligibility Criteria
Inclusion
- Chronic stable angina - to see if this improves
- Previous positive exercise tolerance test - to ensure that repeating it yields a result
- Disease not suitable for coronary intervention (Coronary artery bypass grafting or angioplasty) - so that best routine care is not withheld
- Do not have overt diabetes - work on this is being undertaken elsewhere
- Body mass index (BMI) greater than 25
Exclusion
- Diabetes mellitus - see above
- Liver failure (ALT\>70U/l, AST\>80U/l)
- Renal failure (creatinine \> 130mmol/l)
- Cardiac failure - rosiglitazone is contraindicated in those with NYHA 3 and 4 cardiac failure
- Physical disability - if it precludes treadmill testing
- Women of child bearing capacity
- Breast feeding mothers
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2006
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00225355
Start Date
February 1 2006
End Date
November 1 2006
Last Update
February 19 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiology Department, Glasgow Royal Infirmary
Glasgow, United Kingdom, G4 0SF